Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Education & Resources

Slides

Inclisiran and the ORION clinical development programmeInclisiran and the ORION clinical development programmeEvolution of PCSK9 inhibitors: Pipedream or Evidence based RealityEvolution of PCSK9 inhibitors: Pipedream or Evidence based RealityHow do we recognize FH in clinical practice?How do we recognize FH in clinical practice?PCSK9 Inhibitors: A View of Clinical StudiesPCSK9 Inhibitors: A View of Clinical StudiesFH in children and adolescentsFH in children and adolescentsView all slides »

Videos

PlayVIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types
VIDEO: Prof Stephen Nicholls Effect of alirocumab on MI types
PlayVIDEO: Novel PCSK9 therapeutics
VIDEO: Novel PCSK9 therapeutics
PlayVIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids
VIDEO: BANTING study in type 2 diabetes: evolocumab improves lipid goals and postprandial lipids
PlayVIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points
VIDEO: AHA/ACC 2018 Cholesterol Guidelines also have good points
View all videos »

Events

Cardiometabolic Health Congress 2019 (CMHC 2019)
Event start date: 3 May 2019
Pheonix, USA

Asian Pacific Society of Cardiology Congress 2019 (APSC 2019)
Event start date: 22 May 2019
Manila, The Philippines

87th European Atherosclerosis Society
Event start date: 26 May 2019
Maastricht, The Netherlands

View all events »

Trials

View all trials »

Links

View all links »

Guidelines & Consensus Guidance

View all guidelines »

Archived articles

View the archive »

Find out more

Further reading
Most popular searches
Authors

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.
Educational Partners and Supporters
AmgenThe Medicines CompanySanofi RegeneronAmgenThe Medicines CompanySanofi RegeneronAmgenThe Medicines CompanySanofi RegeneronThe Medicines CompanySanofi Regeneron
© Copyright 2019 PCSK9 Forum. All rights reserved